Trial Profile
A Pilot Study to Evaluate the Safety of Neoadjuvant Nivolumab Alone or in Combination With Ipilimumab for Cisplatin-Ineligible Patients With Muscle Invasive Bladder Cancer (CA209-9DJ)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Feb 2024
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Bladder cancer; Pelvic cancer; Renal cancer; Ureteral neoplasms; Urogenital cancer
- Focus Therapeutic Use
- Acronyms CA209-9DJ
- 01 Feb 2024 Planned End Date changed from 1 Jan 2024 to 1 Jan 2025.
- 01 Feb 2024 Planned primary completion date changed from 1 Jan 2024 to 1 Jan 2025.
- 27 Jan 2024 Updated Results (n=17) assessing safety and efficacy of Neoadjuvant nivolumab (N) + ipilimumab (I) in cisplatin-ineligible patients with upper tract urothelial cancer presented at the 2024 Genitourinary Cancers Symposium